Literature DB >> 26834846

Latest therapeutic advances in musculoskeletal disease from the ACR 2015 annual conference.

David M Reid1, Gordon Mallarkey2.   

Abstract

Entities:  

Year:  2016        PMID： 26834846      PMCID： PMC4707419          DOI： 10.1177/1759720X15624062

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN： 1759-720X            Impact factor:   5.346


× No keyword cloud information.
  5 in total

1.  Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

Authors:  Philip J Mease; Iain B McInnes; Bruce Kirkham; Arthur Kavanaugh; Proton Rahman; Désirée van der Heijde; Robert Landewé; Peter Nash; Luminita Pricop; Jiacheng Yuan; Hanno B Richards; Shephard Mpofu
Journal:  N Engl J Med       Date:  2015-10       Impact factor: 91.245

2.  Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Iain B McInnes; Philip J Mease; Bruce Kirkham; Arthur Kavanaugh; Christopher T Ritchlin; Proton Rahman; Désirée van der Heijde; Robert Landewé; Philip G Conaghan; Alice B Gottlieb; Hanno Richards; Luminita Pricop; Gregory Ligozio; Manmath Patekar; Shephard Mpofu
Journal:  Lancet       Date:  2015-06-28       Impact factor: 79.321

3.  Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.

Authors:  Noortje van Herwaarden; Aatke van der Maas; Michiel J M Minten; Frank H J van den Hoogen; Wietske Kievit; Ronald F van Vollenhoven; Johannes W J Bijlsma; Bart J F van den Bemt; Alfons A den Broeder
Journal:  BMJ       Date:  2015-04-09

4.  A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

Authors:  Jung-Yoon Choe; Nenad Prodanovic; Jaroslaw Niebrzydowski; Ivan Staykov; Eva Dokoupilova; Asta Baranauskaite; Roman Yatsyshyn; Mevludin Mekic; Wieskawa Porawska; Hana Ciferska; Krystyna Jedrychowicz-Rosiak; Agnieszka Zielinska; Jasmine Choi; Young Hee Rho; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2015-08-28       Impact factor: 19.103

5.  A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.

Authors:  Paul Emery; Jiří Vencovský; Anna Sylwestrzak; Piotr Leszczyński; Wieslawa Porawska; Asta Baranauskaite; Vira Tseluyko; Vyacheslav M Zhdan; Barbara Stasiuk; Roma Milasiene; Aaron Alejandro Barrera Rodriguez; Soo Yeon Cheong; Jeehoon Ghil
Journal:  Ann Rheum Dis       Date:  2015-07-06       Impact factor: 19.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.